LATTICE MEDICAL Secures €43 Million Investment to Revolutionize Breast Reconstruction with 3D-Printed Resorbable Implants
A groundbreaking announcement has significantly impacted both the French additive manufacturing landscape and the broader medtech sector across Europe: LATTICE MEDICAL has successfully raised an impressive €43 million in its latest funding round. This substantial investment is earmarked to dramatically accelerate the clinical development of MATTISSE, a pioneering resorbable breast implant conceived and manufactured using state-of-the-art 3D printing technology. This innovation promises to usher in a new era for breast reconstruction following breast cancer, offering a pathway to outcomes that are more natural, simpler, and ultimately, improve the quality of life for countless women.
Breast cancer remains a formidable global health challenge. According to the World Health Organization (WHO), a staggering 2 million new cases are diagnosed annually, solidifying its position as the most prevalent and deadliest form of cancer among women worldwide. In response to this urgent medical need, numerous initiatives and projects are continually developed. October, globally recognized as Breast Cancer Awareness Month, serves as a crucial period to reflect on advancements and ongoing efforts. It is within this vital context that the dedicated work of Lille-based LATTICE MEDICAL takes center stage. The company is committed to delivering a more natural and effective solution for women who have undergone a mastectomy, embodying its core mission: “To reinvent tissue regeneration solutions to improve the quality of life for patients after cancer.”
Traditional methods of breast reconstruction often involve the use of synthetic implants, which, while effective for many, can present challenges such as capsular contracture, rupture, or the need for subsequent surgeries. LATTISSE MEDICAL’s MATTISSE implant offers a radically different approach. By leveraging the precision and versatility of 3D printing, MATTISSE is designed to be fully resorbable, meaning it gradually dissolves within the body over time. This innovative design allows the patient’s own tissues to naturally regenerate and integrate into the scaffold created by the implant. The result is a natural breast volume and shape, without the long-term presence of a foreign body. This advancement holds immense potential to reduce post-operative complications and significantly enhance patient satisfaction and comfort, marking a monumental step forward in personalized reconstructive surgery.
LATTICE MEDICAL’s journey to this significant Series B funding round reflects a strong trajectory of innovation and investor confidence. The company had previously secured $8 million in 2022, followed by an additional $6 million in funding in 2024. This latest €43 million investment, however, represents a pivotal leap, demonstrating the escalating belief in LATTICE MEDICAL’s potential to disrupt the medical device market. This Series B round was spearheaded by the prestigious SPI Fund, which is managed on behalf of the French government as a critical component of the France 2030 strategic investment plan by Bpifrance. This significant government backing underscores the national importance placed on LATTICE MEDICAL’s pioneering work in advanced medical technology and its contribution to French industrial sovereignty.
The round also saw robust support from other key investors, including Blast.Club, Sprim, and a consortium of qualified investors grouped within TIDJEE. Furthermore, long-standing shareholders such as the EIC Fund, Captech Santé, Nord France Amorçage, and FIRA Nord Est reaffirmed their commitment, highlighting the consistent trust in LATTICE MEDICAL’s vision and execution. This diverse coalition of public and private investors provides LATTICE MEDICAL with a robust financial foundation to execute its ambitious growth strategy.
In practical terms, this substantial capital injection will enable LATTICE MEDICAL to accelerate several critical initiatives. Foremost among these is the rapid advancement of the clinical development of both MATTISSE and RODIN, with the strategic objective of bringing these groundbreaking products to market as swiftly as possible. This involves expanding the scope and speed of clinical trials, navigating stringent regulatory pathways, and gathering comprehensive data to support broad adoption. Accelerating market access means that more patients can benefit from these innovative solutions sooner, profoundly impacting their recovery and quality of life after cancer.
Beyond clinical development, a significant portion of the funding will be allocated to scaling LATTICE MEDICAL’s industrial capacity. This is crucial for transitioning from research and development to large-scale, high-quality manufacturing of complex medical devices. Investments will likely include state-of-the-art 3D printing facilities, advanced cleanroom environments, automation technologies, and robust quality control systems to ensure precision, consistency, and compliance with the highest medical standards. Expanding manufacturing capabilities is not just about producing more units; it’s about establishing a resilient and efficient supply chain capable of meeting global demand. Furthermore, the company plans to strengthen its commercial presence, initially within Europe, and then expanding strategically into international markets. This global expansion will involve building robust sales, marketing, and distribution networks, and potentially forging strategic partnerships to ensure widespread access to their transformative technologies.
The innovative use of additive manufacturing is central to LATTICE MEDICAL’s success. 3D printing allows for the creation of intricate, patient-specific geometries that would be impossible with traditional manufacturing methods. For MATTISSE, this means fabricating a porous scaffold with a tailored architecture that encourages the ingrowth of native tissue while maintaining structural integrity during the initial healing phase. The ability to precisely control the internal structure and porosity of the implant is key to facilitating optimal tissue regeneration and ensuring the implant’s biodegradability at a controlled rate, making it a truly revolutionary advancement in medical device manufacturing and tissue engineering.
Julien Payen, CEO of LATTICE MEDICAL, articulates the profound significance of this milestone: “This fundraising is a real turning point for LATTICE MEDICAL. It allows us to pursue our mission: to reinvent tissue reconstruction after cancer, while building an innovative and industrial French medtech company that contributes to the health of the region and the quality of life of patients.” His statement underscores not only the company’s commitment to advancing medical science but also its dedication to fostering economic growth and job creation within France. This investment solidifies LATTICE MEDICAL’s position as a key player in the global medtech arena, driving forward solutions that address critical unmet needs in patient care.
The success of LATTICE MEDICAL is a testament to the transformative potential of combining cutting-edge additive manufacturing with a deep understanding of biological processes. It signals a future where personalized, regenerative medicine becomes the standard, particularly in challenging fields like post-cancer reconstruction. This innovative approach promises not just to restore physical form but to significantly enhance the overall well-being and confidence of patients, empowering them to reclaim their lives after a life-altering diagnosis and treatment. The French medtech sector, supported by initiatives like France 2030, is clearly emerging as a global leader in fostering such groundbreaking advancements.
What are your thoughts on this monumental fundraising round for LATTICE MEDICAL and its implications for breast cancer patients worldwide? We invite you to share your insights in a comment below or connect with us on our LinkedIn or Facebook pages! Furthermore, don’t miss out on the latest advancements in additive manufacturing by signing up for our free weekly Newsletter to receive top 3D printing news directly in your inbox. For more visual content, explore all our videos on our YouTube channel. If your interest lies specifically in medical and dental 3D printing news, a wealth of information awaits you on our dedicated page HERE.
*Cover Image Credit: LATTICE MEDICAL